Biosimilars

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

A biologics license application has been submitted to the FDA for the rituximab biosimilar ABP 798.

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.

Julie R. Gralow, MD, discusses the science of biosimilars and their implementation in breast cancer.

Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.

John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

The trastuzumab biosimilar Ogivri (MYL-1401O; trastuzumab-dkst) has been launched in the United States for all indications of the reference product, including the treatment of patients with HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma.

The Chinese-manufactured trastuzumab biosimilar HLX02 demonstrated similar objective response rates to the reference product at 24 weeks in patients with treatment-naïve or recurrent metastatic HER2-positive breast cancer.

Lee S. Schwartzberg, MD, FACP, discusses the development and approval process for biosimilars and explains how their availability could drive down out-of-pocket costs for patients.

The FDA has accepted a biologics license application for the proposed bevacizumab biosimilar SB8.

Bradley G. Somer, MD, discusses the emergence of biosimilars in oncology

The slate of biosimilars for cancer is growing, and with this expansion the potential for price competition has improved.

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.

Jim M. Koeller, MS FHOPA, discusses the heterogeneity of biologics.

Bradley G. Somer, MD, discusses lowering the cost of cancer care with biosimilars.

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.